Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy

Cancer Science

Volumn 101, Issue 8, 2010, Pages 1828-1833

  Matsuura, Motoki ^a   Suzuki, Takahiro ^a   Saito, Tsuyoshi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; OSTEOPONTIN; RNA; SIMVASTATIN; SMALL INTERFERING RNA; VERY LATE ACTIVATION ANTIGEN 5;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER THERAPY; CELL INVASION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; GENETIC TRANSFECTION; HUMAN; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ADENOCARCINOMA, CLEAR CELL; CELL LINE, TUMOR; EXTRACELLULAR MATRIX; FEMALE; HUMANS; INTEGRINS; NEOPLASM INVASIVENESS; OSTEOPONTIN; OVARIAN NEOPLASMS; RNA INTERFERENCE; SIMVASTATIN;

EID: 77954844604     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01615.x     Document Type: Article

References (48)

1. Sugiyama T, Kamura T, Kigawa J. Clinical characteristic of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000, 88:2584-9.
2. Tsuchiya A, Sakamoto M, Yasuda J. Expression profiling in ovarian clear cell carcinoma. Identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target therapy of ovarian clear cell carcinoma. Am J Pathol 2003, 163:2503-12.
3. Tammela J, Geisler JP, Eskew PN, Geisler HE. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaecol Oncol 1998, 19:438-40.
4. Kato N, Motoyama T. Overexpression of Osteopontin in clear cell carcinoma of the ovary: close association with HNF-1 beta expression. Histopathology 2008, 52:682-8.
5. Kim JH, Skates SJ, Uede T. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002, 13:1671-9.
6. Senkel S, Lucas B, Klein-Hitpass L, Ryffel GU. Identification of target genes of the transcription factor HNF-1beta and HNF-1alfa in a human embryonic kidney cell line. Biochim Biophys Acta 2005, 20:179-90.
7. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000, 11:279-303.
8. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979, 16:885-93.
9. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland P. The regulation and role of Osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006, 17:463-74.
10. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 2007, 102:859-68.
11. Jain S, Chakraborty G, Kundu GC. The crucial role of cyclooxygenase-2 in Osteopontin-induced protein kinase C alpha/c-Src/IkB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res 2006, 66:38-48.
12. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Elevated circulating level of Osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007, 57:373-80.
13. Matusan K, Dordevic G, Stipic D, Mozetic V, Lucin K. Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol 2006, 94:325-31.
14. Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of Osteopontin expression in human gastric carcinoma. Ann Surg Oncol 2007, 14:3419-27.
15. Apparao KBC, Murray MJ, Fritz MA. Osteopontin and its receptor alpha v beta 3 integrin are coexpressed in the human endometrium during the menstrual cycle but regulated differentially. J Clin Endocrinol Metab 2001, 86:4991-5000.
16. Nakae M, Iwamoto I, Fujino T. Preoperative plasma Osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res 2006, 32:309-14.
17. Schorge JO, Drake RD, Lee H. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004, 10:3474-8.
18. Visintin I, Feng Z, Longton G. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008, 14:1065-72.
19. Coppola D, Szabo M, Boulware D. Correlation of Osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004, 10:184-90.
20. Chakraborty G, Jain S, Behera R. The multifaceted roles of Osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006, 6:819-30.
21. Kon S, Maeda M, Segawa T. Antibodies to different peptides in Osteopontin reveal complexities in the various secreted forms. J Cell Biochem 2000, 77:487-98.
22. Hu DD, Lin ECK, Kovach NL, Hoyer JR, Smith JW. A biochemical characterization of binding of Osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 1995, 270:26232-8.
23. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM. The adhesive and migratory effects of Osteopontin are mediated via distinct cell surface Integrins. J Clin Invest 1995, 95:713-24.
24. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006, 16:79-87.
25. Van der Flier A, Sonnenberg A. Function and interactions on integrins. Cell Tissue Res 2001, 305:285-98.
26. Wai PY, Kuo PC. The role of Osteopontin in tumor metastasis. J Surg Res 2004, 121:228-41.
27. Davidson B, Goldberg I, Reich R. Alpha v- and beta 1- integrin subunits are commonly expressed in malignant effusion from ovarian carcinoma patients. Gynecol Oncol 2003, 90:248-57.
28. Sawada K, Mitra AK, Radjabi AR. Loss of E-Cadherin promotes ovarian cancer metastasis via alpha 5-Integrin, which is atherapeutic target. Cancer Res 2008, 68:2329-39.
29. Johnson GA, Burghardt RC, Spencer TE, Newton GR, Ott TL, Bazer FW. Ovine Osteopontin: Osteopontin and alpha v beta 3 integrin expression in the uterus and conceptus during the periimplantation period. Biol Reprod 1999, 61:892-9.
30. Jemal A, Murray T, Ward E. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
31. Bois AD, Luck HJ, Meier W. A randomized clinical trial of Cisplatin/Paclitaxel versus Carboplatin/Paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003, 95:1320-9.
32. Enomoto T, Kuragaki C, Yamasaki M. Is clear cell carcinoma and micinous carcinoma of ovary sensitive to combination chemotherapy with paclitaxel and carboplatin. Proc Am Soc Clin Oncol 2003, 22:447 (abstract 1797).
33. Johnston NIF, Gunasekharan VK, Ravindranath A, O'Connel C, Johnston PG, EI-Tanani MK. Osteopontin as a target for cancer therapy. Front Biosci 2008, 13:4361-72.
34. Weber GF. The metastasis gene Osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001, 1552:61-85.
35. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kB-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001, 276:44926-35.
36. Song G, Cai QF, Mao YB, Ming YL, Bao SD, Ouyang GL. Osteopontin promotes ovarian cancer progression and cell survival and increase HIF-1 alpha expression through the PI3-K/Akt pathway. Cancer Sci 2008, 99:1901-7.
37. Cantor H, Shinohara ML. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat Rev Immunol 2009, 9:137-41.
38. Zohar R, Suzuki N, Suzuki K. Intracellular Osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 2000, 184:118-30.
39. Zohar R, Lee W, Arora P, Cheifetz S, McCulloch C, Sodek J. Single cell analysis of intracellular Osteopontin in osteogenic cultures of fetal rat calvarial cells. J Cell Physiol 1997, 170:88-100.
40. Standal T, Borset M, Sundan A. Role of Osteopontin in adhesion, migration, cell survival and remodeling. Exp Oncol 2004, 26:179-84.
41. Takemoto M, Kitahara M, Yokote K. NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. Br J Pharmacol 2001, 133:83-8.
42. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2008, 17:88-94.
43. Fujiwara K, Tsubaki M, Yamazoe Y. Flivastatin induces apoptosis on human tongue carcinoma cell line HSC-3. Yakugaku Zasshi 2008, 128:153-8.
44. Koyuturk M, Ersoz M, Altiok N. Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Neurosci Lett 2004, 370:212-7.
45. Clutterbuck RD, Millar BC, Powles RL. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol 1998, 102:522-7.
46. Lishner M, Bar-Sef A, Elis A. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med 2001, 49:319-24.
47. Mi Z, Guo H, Russell MB. RNA aptamer blockade of Osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009, 17:153-61.
48. Zhao J, Dong L, Lu B. Down-regulation of Osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008, 135:956-68.